Archive for the ‘biotech/medical’ category: Page 7

May 3, 2024

Nanotubes, nanoparticles and antibodies detect tiny amounts of fentanyl

Posted by in categories: biotech/medical, chemistry, nanotechnology

A research team at the University of Pittsburgh led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich School of Arts and Sciences, has developed a fentanyl sensor that is six orders of magnitude more sensitive than any electrochemical sensor for the drug reported in the past five years. The portable sensor can also tell the difference between fentanyl and other opioids.

May 3, 2024

Researcher creates optical magnetometer prototype that detects errors in MRI scans

Posted by in categories: biotech/medical, electronics

Hvidovre Hospital has the world’s first prototype of a sensor capable of detecting errors in MRI scans using laser light and gas. The new sensor, developed by a young researcher at the University of Copenhagen and Hvidovre Hospital, can thereby do what is impossible for current electrical sensors—and hopefully pave the way for MRI scans that are better, cheaper and faster.

May 2, 2024

Comparing Robotic Radical Prostatectomy and PGC for Cancer Control

Posted by in categories: biotech/medical, robotics/AI

The following is a summary of “Comparative Effectiveness of Partial Gland Cryoablation Versus Robotic Radical Prostatectomy for Cancer Control,” published in the April 2024 issue of Urology by Zhu et al.

In this study, researchers address the notable gap in high-level evidence comparing oncologic endpoints for partial gland ablation, where most existing series rely on prostate-specific antigen (PSA) rather than biopsy endpoints. The objective was to conduct a comprehensive comparison of oncologic outcomes between partial gland cryoablation (PGC) and radical prostatectomy (RP) for the management of prostate cancer.

Through a retrospective, single-center analysis, investigators examined a cohort of subjects treated with either PGC (n = 98) or RP (n = 536) as primary treatment for intermediate-risk (Gleason grade group [GG] 2–3) prostate cancer between January 2017 and December 2022. Key oncologic endpoints included surveillance biopsies per protocol after PGC and serial PSA testing after RP. The primary outcome of interest was treatment failure, which is defined as the necessity for salvage treatment or metastatic disease development. The study group conducted treatment failure and survival analyses using Cox proportional-hazard regression and Kaplan-Meier survival curves. After carefully applying inclusion/exclusion criteria, they compared the PGC (n = 75) and RP (n = 298) groups.

May 2, 2024

Brief anger may impair blood vessel function

Posted by in category: biotech/medical

Research Highlights: When adults became angry after remembering past experiences, the function of cells lining the blood vessels was negatively impaired, which may restrict blood flow.

May 2, 2024

Beyond Limitless: Unveiling the Real NZT-48, Klotho Gene Therapy

Posted by in categories: biotech/medical, life extension, neuroscience

In Limitless, the film’s protagonist is a struggling writer desperate for success. As luck would have it, he is introduced to an experimental drug that unlocks his full potential.

The film was a box office success, and it is easy to see why.

Nootropics, drugs, and various supplements for memory, focus, and mental agility have been used for millennia. The desire to elevate ourselves is universal, much like the quest for longevity–and, unsurprisingly, the two are intertwined.

May 2, 2024

Nano-drugs hitching a ride on bacteria could help treat pancreatic cancer

Posted by in categories: biotech/medical, nanotechnology

Many pancreatic tumors are like malignant fortresses, surrounded by a dense matrix of collagen and other tissue that shields them from immune cells and immunotherapies that have been effective in treating other cancers. Employing bacteria to infiltrate that cancerous fortification and deliver these drugs could aid treatment for pancreatic cancer, according to newly published findings from a team of University of Wisconsin–Madison researchers.

May 2, 2024


Posted by in categories: bioengineering, biotech/medical, nanotechnology

From DNA nanotechnology to synthetic biology.

Shared with Dropbox.

May 2, 2024

Sepsis Builds Immune System to Fight Cancer

Posted by in categories: biotech/medical, information science, neuroscience

Sepsis is a condition in which the body responds improperly. More specifically, the infection causes the organs in the body to shut down. This is a serious illness which could lead to extremely low blood pressure or septic shock. In this case, permanent damage to the lungs, kidneys, liver, and other organs can occur. Unfortunately, if the damage is extensive enough, it could be fatal. Common symptoms associated with sepsis includes alteration of mental status, shallow breathing, sweating out of context, lightheadedness, chills, and other symptoms associated with infection or fever. Sepsis can lead to septic shock and raises the risk of death. Symptoms of septic shock include inability to stand, sleepiness, and extreme confusion. Interestingly, symptoms can vary between people, and it is important to monitor bodily changes to detect sepsis as early as possible. Bacterial, viral, or fungal infections can lead to sepsis including common infections such as pneumonia, urinary tract infections, and burns, among others. It is critical to see a doctor if you suspect you are not getting better or if your symptoms worsen. Early detection of sepsis can help improve survival rate and prevent permanent organ damage. Treatments include antibiotics, increased fluids, vasopressors to increase blood pressure, and steroids. Although scientists and physicians have worked to understand sepsis and how to treat it, other discoveries are yet to be made.

A recent study in Nature Immunology by Dr. Antoine Roquilly from Nantes University in France, demonstrated that patients that experienced sepsis build strong immune cells that aid in the prevention of tumor development. It was previously unknown how the immune landscape was shaped after a patient recovered from sepsis. Roquilly and his team wanted to understand the relationship between these exposed immune cells and the risk of developing cancer in the future.

Roquilly’s research team first analyzed big datasets that consisted of information from patients who survived sepsis. Researchers were able to determine the risk of cancer prevalence up to 10 years following the discharge from the hospital for sepsis patients. Interestingly, sepsis survivors had lower risk of developing cancer compared to those that did not have sepsis.

May 2, 2024

More than 100,000 students try to sue universities over disruption to their studies

Posted by in categories: biotech/medical, education


The pandemic and industrial action has caused massive upheaval in the education system in recent years, and many students feel short-changed.

May 2, 2024

The extraordinary promise of personalised cancer vaccines

Posted by in categories: biotech/medical, neuroscience

Glioblastomas are an extremely aggressive type of brain tumour, which is why the news this week of a vaccine that has shown promise in fighting them is so exciting. And this comes right off the back of the announcement of another trial of the world’s first personalised mRNA vaccine for melanoma, a kind of skin cancer. Ian Sample talks to Prof Alan Melcher of the Institute of Cancer Research about how these vaccines work and whether they could one day be used to target cancer before it is even detectable on scans.

How to listen to podcasts: everything you need to know.

Page 7 of 2,578First4567891011Last